Q4 2017 13F Holders as of 31 Dec 2017
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
99.6M
-
Number of holders
-
260
-
Total 13F shares, excl. options
-
93.8M
-
Shares change
-
-2.01M
-
Total reported value, excl. options
-
$7.28B
-
Value change
-
-$129M
-
Put/Call ratio
-
1.22
-
Number of buys
-
136
-
Number of sells
-
-113
-
Price
-
$77.59
Significant Holders of NEUROCRINE BIOSCIENCES INC - Common Stock (NBIX) as of Q4 2017
299 filings reported holding NBIX - NEUROCRINE BIOSCIENCES INC - Common Stock as of Q4 2017.
NEUROCRINE BIOSCIENCES INC - Common Stock (NBIX) has 260 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 93.8M shares
of 99.6M outstanding shares and own 94.21% of the company stock.
Largest 10 shareholders include FMR LLC (13.3M shares), Vanguard Group Inc (7.13M shares), PRICE T ROWE ASSOCIATES INC /MD/ (6.23M shares), JANUS HENDERSON GROUP PLC (5.77M shares), PERCEPTIVE ADVISORS LLC (5.15M shares), BlackRock Inc. (4.78M shares), BB BIOTECH AG (3.45M shares), WELLINGTON MANAGEMENT GROUP LLP (3.15M shares), FRANKLIN RESOURCES INC (3.07M shares), and Invesco Ltd. (2.73M shares).
This table shows the top 260 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.